Aliases & Classifications for Colitis

MalaCards integrated aliases for Colitis:

Name: Colitis 12 77 30 56 6 45 15 17 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0060180
MeSH 45 D003092
NCIt 51 C26723
SNOMED-CT 69 64226004
ICD10 34 K52.9
UMLS 74 C0009319

Summaries for Colitis

Disease Ontology : 12 An inflammatory bowel disease that involves inflammation located in colon.

MalaCards based summary : Colitis is related to crohn's colitis and crohn's disease. An important gene associated with Colitis is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Benzocaine and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include colon, t cells and neutrophil, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 77 Colitis is an inflammation of the colon. Colitis may be acute and self-limited or long-term. It broadly... more...

Related Diseases for Colitis

Diseases related to Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1096)
# Related Disease Score Top Affiliating Genes
1 crohn's colitis 33.9 CXCL8 IFNG IL1B IL2 NOD2 TNF
2 crohn's disease 33.0 ABCB1 ATG16L1 IL10 IL10RA IL10RB IL23R
3 pyoderma gangrenosum 32.9 CXCL8 NOD2 TNF
4 ulcerative colitis 32.9 ABCB1 ATG16L1 CTNNB1 CXCL8 IFNG IL10
5 pouchitis 32.8 CXCL8 IL10 NOD2
6 inflammatory bowel disease 25, autosomal recessive 32.8 IL10 IL10RA IL10RB
7 gastroenteritis 32.7 CXCL8 IL10 IL1B IL6 TNF
8 dengue shock syndrome 31.8 IL1B IL6 TNF
9 ileocolitis 31.7 MYO9B NOD2 TNF
10 ileitis 31.7 IL17A IL6 MPO NOD2 TNF
11 pyoderma 31.6 CXCL8 NOD2 TNF
12 cytomegalovirus infection 30.8 CXCL8 IL1B IL6 TNF
13 spondyloarthropathy 1 30.8 IL17A NOD2 TNF
14 familial mediterranean fever 30.6 IL1B NOD2 TNF
15 inflammatory bowel disease 30.6 ABCB1 ATG16L1 CXCL8 IFNG IL10 IL10RA
16 aspergillosis 30.5 IFNG IL10 TNF
17 esophagitis 30.5 CXCL8 IL1B IL6
18 acute pancreatitis 30.5 CXCL8 IL10 IL6 MPO
19 pneumonia 30.5 CXCL8 IL10 IL1B IL6 MPO TNF
20 appendicitis 30.5 CXCL8 IL10 IL1B IL6 MPO TNF
21 spinal cord injury 30.5 CXCL8 IL6 TNF
22 cystitis 30.5 CXCL8 IL6 TNF
23 erythema multiforme 30.4 IFNG IL2 TNF
24 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.4 IFNG IL10 IL17A
25 herpes zoster 30.4 IFNG IL10 IL2
26 alopecia areata 30.4 IFNG IL2 TNF
27 fasciitis 30.4 CXCL8 IL6 TNF
28 pericarditis 30.4 IFNG IL1B IL6 TNF
29 hidradenitis 30.4 IL17A NOD2 TNF
30 kawasaki disease 30.4 IL10 IL6 TNF
31 spondylitis 30.3 IL17A IL23R IL6 NOD2 TNF
32 peritonitis 30.3 CXCL8 IL10 IL1B IL6 MPO TNF
33 hidradenitis suppurativa 30.3 IL17A NOD2 TNF
34 acquired immunodeficiency syndrome 30.2 IFNG IL10 IL1B IL2 IL6 TNF
35 neuritis 30.2 IFNG IL1B TNF
36 arthritis 30.2 CXCL8 IFNG IL10 IL17A IL1B IL6
37 aplastic anemia 30.2 IFNG IL2 IL6 TNF
38 acute generalized exanthematous pustulosis 30.2 CXCL8 IL17A
39 wells syndrome 30.2 CXCL8 IL1B IL2
40 autoimmune inner ear disease 30.2 MPO TNF
41 hematopoietic stem cell transplantation 30.1 IFNG IL10 IL2 IL6 TNF
42 reactive arthritis 30.1 IFNG IL10 IL17A TNF
43 endomyocardial fibrosis 30.1 IL10 TNF
44 hepatitis a 30.1 IFNG IL10 TNF
45 obstructive jaundice 30.1 CXCL8 IL6 TNF
46 graft-versus-host disease 30.1 IFNG IL10 IL1B IL2 IL6 TNF
47 inflammatory bowel disease 5 30.1 ATG16L1 IL23R NOD2
48 necrotizing fasciitis 30.1 CXCL8 IL2 IL6
49 uveitis 30.1 IFNG IL10 IL17A NOD2 TNF
50 bronchiolitis 30.1 CXCL8 IFNG IL10 IL17A IL6 TNF

Graphical network of the top 20 diseases related to Colitis:



Diseases related to Colitis

Symptoms & Phenotypes for Colitis

GenomeRNAi Phenotypes related to Colitis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.88 CXCL8 IL10 IL17A IL1B IL2 MPO
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.88 CXCL8 IL10 IL17A IL1B IL2 MPO

MGI Mouse Phenotypes related to Colitis:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.41 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
2 digestive/alimentary MP:0005381 10.37 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
3 homeostasis/metabolism MP:0005376 10.36 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
4 immune system MP:0005387 10.36 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
5 growth/size/body region MP:0005378 10.34 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RB
6 cellular MP:0005384 10.33 ATG16L1 CTNNB1 IFNG IL10 IL10RA IL10RB
7 cardiovascular system MP:0005385 10.3 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL1B
8 endocrine/exocrine gland MP:0005379 10.29 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RB
9 mortality/aging MP:0010768 10.21 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RB
10 craniofacial MP:0005382 10.08 CTNNB1 IFNG IL10 IL17A IL1B SMAD4
11 liver/biliary system MP:0005370 10.06 ABCB1 CTNNB1 IFNG IL10 IL10RB IL2
12 muscle MP:0005369 9.92 ATG16L1 CTNNB1 IFNG IL10 IL6 MPO
13 neoplasm MP:0002006 9.91 CTNNB1 IFNG IL10 IL1B IL2 IL23R
14 no phenotypic analysis MP:0003012 9.76 ABCB1 CTNNB1 IFNG IL10 IL17A IL2
15 respiratory system MP:0005388 9.56 CTNNB1 IFNG IL10 IL10RB IL17A IL2
16 skeleton MP:0005390 9.28 CTNNB1 IFNG IL10 IL17A IL1B IL6

Drugs & Therapeutics for Colitis

Drugs for Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 491)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
2
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
3
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-03-3
4
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 5754
5
Azathioprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 446-86-6 2265
6
Infliximab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 170277-31-3
7
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
8
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6, 15438-31-0 23925 27284
9
leucovorin Approved Phase 4,Phase 2,Not Applicable 58-05-9 6006 143
10
Tocopherol Approved, Investigational Phase 4,Phase 2,Not Applicable 1406-66-2 14986
11
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6 32051
12
Copper Approved, Investigational Phase 4 7440-50-8 27099
13
Ofloxacin Approved Phase 4 82419-36-1 4583
14
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
15
Ceftriaxone Approved Phase 4,Phase 2 73384-59-5 5479530 5361919
16
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
17
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 302-25-0
18
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2921-57-5
19
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
20
Sodium Citrate Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 68-04-2
21
Mercaptopurine Approved Phase 4,Phase 3,Phase 2,Not Applicable 50-44-2 667490
22 Vedolizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 943609-66-3
23
Aminosalicylic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65-49-6 4649
24
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2 428863-50-7
25
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 93-14-1 3516
26
Vancomycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1404-90-6 441141 14969
27
Loperamide Approved Phase 4,Phase 3,Phase 2,Not Applicable 53179-11-6 3955
28
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 443-48-1 4173
29
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
30
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
31
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
32
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 53-03-2 5865
33
Tofacitinib Approved, Investigational Phase 4,Phase 3,Phase 1 477600-75-2
34
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 85721-33-1 2764
35
Methotrexate Approved Phase 4,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
36
carbamide peroxide Approved Phase 4 124-43-6
37
Magnesium citrate Approved Phase 4 3344-18-1
38
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 22916-47-8 4189
39
Caffeine Approved Phase 4 58-08-2 2519
40
Dextromethorphan Approved Phase 4 125-71-3 5362449 5360696
41
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
42
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 73590-58-6 4594
43
Losartan Approved Phase 4 114798-26-4 3961
44
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
45
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492 6473866
46
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3 128-13-2 31401
47
Ustekinumab Approved, Investigational Phase 4,Phase 3 815610-63-0
48
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521
49
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
50
Linaclotide Approved Phase 4 851199-59-2 65351

Interventional clinical trials:

(show top 50) (show all 1350)
# Name Status NCT ID Phase Drugs
1 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis Unknown status NCT02962245 Phase 4 berberine;regular treatment
2 Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission Unknown status NCT02412085 Phase 4 Golimumab
3 Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab Unknown status NCT02186886 Phase 4 Golimumab
4 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4 Probiotic
5 Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe Unknown status NCT01630096 Phase 4 Nu-Lytely
6 Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
7 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
8 Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis Unknown status NCT02579733 Phase 4 Azathioprine;Placebo
9 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
10 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
11 Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD Unknown status NCT03059849 Phase 4 Adalimumab
12 Anemia in Inflammatory Bowel Disease Unknown status NCT02760940 Phase 4 oral liposomal iron
13 Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab Unknown status NCT02453776 Phase 4 PRECISION dosing Infliximab
14 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
15 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4 Probiotic;Placebo
16 Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
17 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
18 Antibiotics to Decrease Post ERCP Cholangitis Unknown status NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
19 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
20 Duration of Antibiotic Therapy in Community - Acquired Pneumonia Unknown status NCT01492387 Phase 4
21 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
22 Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) Completed NCT02092285 Phase 4 Golimumab
23 Study of Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis Terminated NCT00209287 Phase 4
24 Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis Recruiting NCT02345733 Phase 4 Antibiotic cocktail
25 Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis Recruiting NCT02921555 Phase 4 Methylprednisolone;Prednisone
26 A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission Recruiting NCT03281304 Phase 4 CP-690,500 5 mg;CP-690,550 10 mg
27 Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis Recruiting NCT02770040 Phase 4 Infliximab
28 Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis Completed NCT01408810 Phase 4 Infliximab
29 Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
30 Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC) Active, not recruiting NCT01716039 Phase 4 MTX 12.5;MTX 25;Adalimumab
31 Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis Recruiting NCT02687724 Phase 4 Golimumab (GLM)
32 Efficacy Study of Granulocytapheresis Plus Steroids vs Steroids Alone in Active Steroid Dependant Ulcerative Colitis Terminated NCT00702611 Phase 4
33 Care Path for the Management of Ulcerative Colitis Terminated NCT01882426 Phase 4
34 Optimization of Golimumab Treatment in Ulcerative Colitis Not yet recruiting NCT03669029 Phase 4 Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg;Golimumab treatment optimization.
35 Predicting Response to Standardized Pediatric Colitis Therapy Completed NCT01536535 Phase 4 Mesalamine;Corticosteroid;Corticosteroids then mesalamine
36 Tolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acid in Ulcerative Colitis Patients Recruiting NCT03581149 Phase 4 Sodium Picosulfate/Magnesium Citrate Laxative;2L polyethylene glycol/ascorbic acid
37 A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis Recruiting NCT02425852 Phase 4 Azathioprine;Infliximab;Prednisolone;Hydrocortisone
38 Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis Recruiting NCT03151525 Phase 4 Azathioprine;Infliximab
39 Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis Recruiting NCT03029143 Phase 4 Vedolizumab IV
40 Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) Completed NCT00446849 Phase 4 MMX Mesalamine
41 Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) Completed NCT02155335 Phase 4 Prefilled Syringe delivery of Golimumab;Smartject Device delivery of Golimumab
42 EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis Not yet recruiting NCT03679546 Phase 4 Infliximab;Vedolizumab Injection
43 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
44 Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis Completed NCT01201122 Phase 4 Mesalamine
45 Intermittent Treatment After Reaching the taRget With Golimumab for ulcErative coliTis - (TARGET) Not yet recruiting NCT02425865 Phase 4 GOLIMUMAB
46 Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). Completed NCT02318667 Phase 4
47 Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis Recruiting NCT01941589 Phase 4 oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone;corticosteroids only
48 Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease Completed NCT02559713 Phase 4 Vedolizumab
49 Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis Completed NCT01124149 Phase 4 MMX mesalamine/ mesalazine
50 Asacol Dosing Study for Active Ulcerative Colitis Completed NCT00194818 Phase 4 Asacol (mesalamine)

Search NIH Clinical Center for Colitis

Cochrane evidence based reviews: colitis

Genetic Tests for Colitis

Genetic tests related to Colitis:

# Genetic test Affiliating Genes
1 Colitis 30

Anatomical Context for Colitis

MalaCards organs/tissues related to Colitis:

42
Colon, T Cells, Neutrophil, Liver, Testes, Bone, Monocytes

The Foundational Model of Anatomy Ontology organs/tissues related to Colitis:

20
Colon

Publications for Colitis

Articles related to Colitis:

(show top 50) (show all 11577)
# Title Authors Year
1
Electroacupuncture and Moxibustion Improved Anxiety Behavior in DSS-Induced Colitis Mice. ( 30881446 )
2019
2
Chronic colitis-induced visceral pain is associated with increased anxiety during quiescent phase. ( 30735453 )
2019
3
Leflunomide-induced colitis in association with enterocutaneous fistula in an immunosuppressed patient with renal transplant and rheumatoid arthritis. ( 30820830 )
2019
4
Combined Nutraceuticals: A Novel Approach to Colitis-Associated Colorectal Cancer? ( 30862196 )
2019
5
Colorectal cancer and dysplasia risk in patients with ulcerative colitis at a tertiary referral center in Turkey. ( 30843860 )
2019
6
Pretreatment with a Heat-Killed Probiotic Modulates the NLRP3 Inflammasome and Attenuates Colitis-Associated Colorectal Cancer in Mice. ( 30823406 )
2019
7
The inhibitory effect of polysaccharide from Rhizopus nigricans on colitis-associated colorectal cancer. ( 30784912 )
2019
8
Whole Exome Sequencing of Ulcerative Colitis-associated Colorectal Cancer Based on Novel Somatic Mutations Identified in Chinese Patients. ( 30794281 )
2019
9
Surveillance Colonoscopy for Ulcerative Colitis-Associated Colorectal Cancer Offers Better Overall Survival in Real-World Surgically Resected Cases. ( 30747769 )
2019
10
Loss of RUNX3 Immunoreactivity in Non-Neoplastic Rectal Mucosa May Predict the Occurrence of Ulcerative Colitis-Associated Colorectal Cancer. ( 30763934 )
2019
11
The germ-free mice monocolonization with Bacteroides fragilis improves azoxymethane/dextran sulfate sodium induced colitis-associated colorectal cancer. ( 30706742 )
2019
12
Heterozygous knockout insulin-like growth factor-1 receptor (IGF-1R) regulates mitochondrial functions and prevents colitis and colorectal cancer. ( 30611867 )
2019
13
Mouse Model of Colitis-Associated Colorectal Cancer (CAC): Isolation and Characterization of Mucosal-Associated Lymphoid Cells. ( 30465204 )
2019
14
The recruitment of extra-intestinal cells to the injured mucosa promotes healing in radiation enteritis and chemical colitis in a mouse parabiosis model. ( 30617302 )
2019
15
Oral Vancomycin Induces and Maintains Remission of Ulcerative Colitis in the Subset of Patients With Associated Primary Sclerosing Cholangitis. ( 30838381 )
2019
16
Fidaxomicin and Fecal Microbiota Transplants for Severe Clostridium difficile Colitis. ( 30601771 )
2019
17
Trends in Incidence and Outcomes of Clostridium difficile Colitis in Hospitalized Patients of Febrile Neutropenia: A Nationwide Analysis. ( 30614941 )
2019
18
Nonsteroidal Anti-inflammatory Drugs Alter the Microbiota and Exacerbate Clostridium difficile Colitis while Dysregulating the Inflammatory Response. ( 30622186 )
2019
19
Clostridium difficile Colitis Prevention and Treatment. ( 30689174 )
2019
20
Prolonged non-operative management of clostridium difficile colitis is associated with increased mortality, complications, and cost. ( 30709552 )
2019
21
Clostridium difficile colitis in patients undergoing surgery for hip fractures: an analysis of 17,474 patients. ( 30799640 )
2019
22
Development of a Standardized Scoring System to Assess a Murine Model of Clostridium difficile Colitis. ( 30892111 )
2019
23
Thrombin generation is increased in patients with Clostridium difficile colitis - a pilot study. ( 30907672 )
2019
24
Enterotoxigenic Clostridium perfringens Infection as an Adverse Event After Faecal Microbiota Transplantation in Two Patients With Ulcerative Colitis and Recurrent Clostridium difficile Infection: A Neglected Agent in Donor Screening. ( 30852608 )
2019
25
Emu Oil reduces disease severity in a mouse model of chronic ulcerative colitis. ( 30907169 )
2019
26
A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. ( 30908297 )
2019
27
Nivolumab-induced colitis in a patient with malignant melanoma: A case report and immunological analysis. ( 30908699 )
2019
28
Off-label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis. ( 30908719 )
2019
29
Change in Renal Glomerular Collagens and Glomerular Filtration Barrier-Related Proteins in a Dextran Sulfate Sodium-Induced Colitis Mouse Model. ( 30909435 )
2019
30
Intravenous Immunoglobulin Therapy Eliminates Candidaalbicans and Maintains Intestinal Homeostasis in a Murine Model of Dextran Sulfate Sodium-Induced Colitis. ( 30909599 )
2019
31
Relative risk of microscopic colitis in dermatomyositis. ( 30910660 )
2019
32
The Synergistic Role of Diet and Exercise in the Prevention, Pathogenesis, and Management of Ulcerative Colitis: An Underlying Metabolic Mechanism. ( 30911221 )
2019
33
Combination of oral vancomycin and intra-colonic vancomycin: Successful treatment of complicated pseudomembranous colitis in a child patient. ( 30911393 )
2019
34
DUBLIN (Degree of Ulcerative colitis Burden of Luminal INflammation) score, a simple method to quantify inflammatory burden in Ulcerative Colitis. ( 30911757 )
2019
35
Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. ( 30914450 )
2019
36
Endoscopic Submucosal Dissection for Colitis-Associated Dysplasia. ( 30914628 )
2019
37
The Impact of Lactobacillus plantarum on the Gut Microbiota of Mice with DSS-Induced Colitis. ( 30915354 )
2019
38
MiR-146a regulates the development of ulcerative colitis via mediating the TLR4/MyD88/NF-κB signaling pathway. ( 30915760 )
2019
39
European Crohn's and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease. ( 30820529 )
2019
40
Agmatine ameliorates acetic acid-induced colitis in rats: involvement of nitrergic system. ( 30821531 )
2019
41
Inhibition of tumor necrosis factor alpha and increased of interleukin 10 by Lactobacillus: a molecular mechanism protection against TNBS-induced ulcerative colitis in chicks. ( 30821556 )
2019
42
Association between dietary iron and zinc intake and development of ulcerative colitis: A case-control study in Japan. ( 30821862 )
2019
43
Dietary Protein Intake Level Modulates Mucosal Healing and Mucosa-Adherent Microbiota in Mouse Model of Colitis. ( 30823387 )
2019
44
Purification of 3, 4-dihydroxyphenylethyl alcohol glycoside from Sargentodoxa cuneata (Oliv.) Rehd. et Wils. and its protective effects against DSS-induced colitis. ( 30824734 )
2019
45
Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. ( 30826279 )
2019
46
Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike-report of new cases and review of the literature. ( 30826963 )
2019
47
Ulcerative Colitis: Shifting Sands. ( 30827006 )
2019
48
Flexible Sigmoidoscopy Rather than Colonoscopy Is Adequate for the Diagnosis of Ipilimumab-Associated Colitis. ( 30830228 )
2019
49
High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis. ( 30830524 )
2019
50
Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis. ( 30830573 )
2019

Variations for Colitis

ClinVar genetic disease variations for Colitis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh37 Chromosome 22, 29091857: 29091857
2 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh38 Chromosome 22, 28695869: 28695869
3 FLNA NM_001456.3(FLNA): c.7439C> A (p.Thr2480Asn) single nucleotide variant Uncertain significance rs909387820 GRCh38 Chromosome X, 154349738: 154349738
4 FLNA NM_001456.3(FLNA): c.7439C> A (p.Thr2480Asn) single nucleotide variant Uncertain significance rs909387820 GRCh37 Chromosome X, 153578106: 153578106
5 CIITA NM_000246.3(CIITA): c.3344G> A (p.Ser1115Asn) single nucleotide variant Uncertain significance GRCh37 Chromosome 16, 11017111: 11017111
6 CIITA NM_000246.3(CIITA): c.3344G> A (p.Ser1115Asn) single nucleotide variant Uncertain significance GRCh38 Chromosome 16, 10923254: 10923254

Expression for Colitis

Search GEO for disease gene expression data for Colitis.

Pathways for Colitis

Pathways related to Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.13 CTNNB1 CXCL8 IFNG IL10 IL10RA IL10RB
2
Show member pathways
13.97 CTNNB1 CXCL8 IL10 IL10RA IL10RB IL17A
3
Show member pathways
13.79 CXCL8 IFNG IL10 IL10RA IL10RB IL17A
4
Show member pathways
13.66 CXCL8 IFNG IL10 IL10RA IL10RB IL17A
5
Show member pathways
13.54 CXCL8 IL10 IL10RA IL10RB IL17A IL1B
6
Show member pathways
13.46 CXCL8 IFNG IL10 IL10RA IL10RB IL17A
7
Show member pathways
13.34 CTNNB1 CXCL8 IL10 IL10RA IL10RB IL17A
8
Show member pathways
13.33 ATG16L1 CXCL8 IFNG IL10 IL1B IL2
9
Show member pathways
13.09 CTNNB1 CXCL8 IL10RA IL10RB IL1B IL6
10 12.97 CTNNB1 CXCL8 IFNG IL2 IL23R IL6
11
Show member pathways
12.82 CXCL8 IFNG IL1B IL6 TNF
12
Show member pathways
12.77 ABCB1 CXCL8 IFNG IL10 IL10RA IL10RB
13
Show member pathways
12.76 IFNG IL10 IL10RA IL10RB IL2 TNF
14 12.72 IFNG IL10 IL17A IL1B IL2 MPO
15
Show member pathways
12.69 CXCL8 IFNG IL1B IL2 IL6 TNF
16
Show member pathways
12.6 IFNG IL10 IL17A IL1B IL2 IL6
17
Show member pathways
12.56 IFNG IL10 IL10RA IL10RB IL2 IL23R
18
Show member pathways
12.49 IFNG IL1B IL2 IL6 MPO TNF
19
Show member pathways
12.49 CXCL8 IFNG IL17A IL1B IL6 TNF
20 12.47 CTNNB1 IL2 IL6 SMAD4 TNF
21
Show member pathways
12.43 CXCL8 IFNG IL1B IL6 TNF
22
Show member pathways
12.43 CXCL8 IFNG IL10 IL17A IL1B IL2
23
Show member pathways
12.43 IFNG IL10 IL10RA IL10RB IL1B IRGM
24
Show member pathways
12.43 IFNG IL10 IL10RB IL17A IL1B IL2
25 12.37 IFNG IL10 IL10RA IL10RB IL1B IL6
26
Show member pathways
12.35 IL10 IL1B IL2 IL6 TNF
27 12.35 CTNNB1 CXCL8 IL10 IL1B IL6 TNF
28
Show member pathways